Leflunomide for the successful management of juvenile Cogan's syndrome

Clin Rheumatol. 2009 Dec;28(12):1453-5. doi: 10.1007/s10067-009-1263-3. Epub 2009 Aug 29.

Abstract

Cogan's syndrome (CS) is a rare multisystemic disorder characterized by inflammatory eye diseases and vestibuloauditory dysfunctions. It is prone to be misdiagnosed or overlooked, and the prognosis of those delayed-diagnosed CS is not optimistic. Despite isolated patient responses to systemic treatment including steroids and methotrexate, there is currently no general consensus on an effective treatment for CS. We present a case of Cogan's syndrome remission associated with leflunomide (LEF) in a juvenile patient. To date, there is no such report on CS, especially in children, which is successfully treated by LEF in combination with glucocorticoids.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Blood Sedimentation
  • Child
  • Cogan Syndrome / blood
  • Cogan Syndrome / drug therapy*
  • Cogan Syndrome / pathology
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use*
  • Humans
  • Isoxazoles / therapeutic use*
  • Leflunomide
  • Male
  • Methylprednisolone / therapeutic use*
  • Prednisolone / therapeutic use*
  • Remission Induction
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Glucocorticoids
  • Isoxazoles
  • Prednisolone
  • Leflunomide
  • Methylprednisolone